Cognitive Screening and Testing in a Biomarker Era

When blood-based biomarker tests and new therapies for Alzheimer’s disease become available, how do we apply cognitive testing to identify who to treat and assess whether treatment is benefiting cognition? Do we need new cognitive tests and methods for screening and monitoring? In this webinar, experts from the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) will discuss these questions.


  • Douglas Galasko, M.D.
  • Kathleen Welsh-Bohmer, M.D.


  • Rhoda Au, Ph.D.
  • Mark Bondi, Ph.D.
  • Ratnavalli Ella Josyula, M.D., D.M.
  • Roos Jutten, Ph.D.
  • Andreas Monsch, Ph.D.
  • Mathew Summers, Ph.D.